Solventum Corp
SOLVHealthcare
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 5, 2026
Next reportFebruary 24, 2027pre-market · forecast 1.825 $/share
Revenue
$1.95B
▼ -7.0% vs prior year YoY
Net income
−$12.00M
▼ -100.9% vs prior year YoY
EPS
-0.07$
▼ -101.0% vs prior year YoY
Net margin
-0.6%
▼ -61.0 pp vs prior year YoY
Revenue▼ -7.0%
Margins (% of revenue)GrossOperatingNet
Net income▼ -100.9%
EPS▼ -101.0%
Financial statements
View 10-Q filed November 5, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $2.08B | $2.07B | $2.16B | $2.10B | $2.00B | $2.01B | $2.21B | $1.95B | ▼ -7.0% |
| Gross profit | $1.12B | $1.11B | $1.18B | $1.14B | $1.03B | $1.10B | $1.29B | $1.06B | ▼ -6.4% |
| Operating income | $136.00M | $152.00M | $214.00M | $1.69B | $125.00M | $81.00M | $181.00M | $68.00M | ▼ -96.0% |
| Net income | $31.00M | $137.00M | $90.00M | $1.27B | $63.00M | $13.00M | $92.00M | −$12.00M | ▼ -100.9% |
| R&D | $199.00M | $193.00M | $189.00M | $183.00M | $174.00M | $189.00M | $178.00M | $181.00M | ▼ -1.1% |
| EPS (diluted) | — | 0.78 $ | 0.51 $ | 7.22 $ | — | 0.07 $ | 0.53 $ | -0.07 $ | ▼ -101.0% |
| Margins (% of revenue) | |||||||||
| Gross | 53.9 % | 53.8 % | 54.4 % | 54.2 % | 51.4 % | 54.7 % | 58.2 % | 54.5 % | ▲ +0.3 pt |
| Operating | 6.6 % | 7.3 % | 9.9 % | 80.6 % | 6.3 % | 4.0 % | 8.2 % | 3.5 % | ▼ -77.1 pt |
| Net | 1.5 % | 6.6 % | 4.2 % | 60.4 % | 3.2 % | 0.6 % | 4.2 % | -0.6 % | ▼ -61.0 pt |
| Balance sheet | |||||||||
| Assets | $14.46B | $14.53B | $15.07B | $13.97B | $14.29B | $14.10B | $14.24B | $14.16B | ▲ +1.4% |
| Liabilities | $11.50B | $11.27B | $11.43B | $8.99B | $9.24B | $9.13B | $9.44B | $9.36B | ▲ +4.2% |
| Equity | $2.96B | $3.26B | $3.65B | $4.99B | $5.05B | $4.97B | $4.80B | $4.80B | ▼ -3.6% |
| Cash | $762.00M | $534.00M | $492.00M | $1.64B | $878.00M | $561.00M | $403.00M | $451.00M | ▼ -72.5% |
| Capital | |||||||||
| Shares outstanding | 172.99M | 173.01M | 173.39M | 173.45M | 173.49M | 173.17M | 170.22M | 169.74M | ▼ -2.1% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.